Through the use of delivery systems, side effects can be reduced due to accurately targeting the tumoral cells (e.g., using polycation gene vectors for delivering lncRNA Maternally Expressed 3 (MEG3) in hepatocellular carcinoma [127], or gold nanoparticles with Tyrosine Aminotransferase (TAT) peptide to deliver specifically into lung cancer cells ASOs against lncRNA MALAT) [128]. This evidence concerns the gene MEG3 and hepatocellular carcinoma.